M2 Macrophages Mediate Sorafenib Resistance by Secreting HGF in a Feed-Forward Manner in Hepatocellular Carcinoma

British Journal of Cancer - United Kingdom
doi 10.1038/s41416-019-0482-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Sorafenib in Hepatocellular Carcinoma

Clinical Medicine. Therapeutics
2009English

TARBP2-mediated Destabilization of Nanog Overcomes Sorafenib Resistance in Hepatocellular Carcinoma

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2019English

The Microenvironmental and Metabolic Aspects of Sorafenib Resistance in Hepatocellular Carcinoma

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

MicroRNA‑223 Promotes Hepatocellular Carcinoma Cell Resistance to Sorafenib by Targeting FBW7

Oncology Reports
MedicineCancer ResearchOncology
2018English

Zinc Finger Protein 703 Induces EMT and Sorafenib Resistance in Hepatocellular Carcinoma by Transactivating CLDN4 Expression

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2020English

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2013English

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2014English

Cytotoxicity of Sorafenib in Human Hepatocellular Carcinoma Cells

Al-Azhar Journal of Pharmaceutical Sciences
2015English

Sorafenib vs Nivolumab in Patients With Hepatocellular Carcinoma

Journal of Liver Research, Disorders & Therapy
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy